Silence Therapeutics (SLNCF) Stock Price, News & Analysis
What Changed
Price Move History
- Daily moves over 5%
- 19 33 sessions, November 4, 2025 to October 30, 2026
- Largest daily move
- +108.5% close of June 15, 2026
- 1-month change
- +63% closing prices, September 23, 2026 to October 30, 2026
Company Description
Silence Therapeutics (OTC: SLNCF) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $1.2B.
SLNCF has gained 63.0% over the past month. The last closing price was $6.52.
For FY2025, Silence Therapeutics reported revenue of $559K with net income of -$88.6M and diluted earnings per share of -$0.63.
This page collects what Stock Titan holds for SLNCF, including price data, latest news, SEC filings, insider trading activity, financial highlights, and short interest trends.
Stock Performance
Silence Therapeutics (SLNCF) closed at $6.52 on October 30, 2026. Over the past month, the price has gained 63.0%.
SLNCF Metrics & Rankings
Price returns through October 30, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Silence Therapeutics has 4 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 0 with negative movement. Key topics include acquisition, management. View all SLNCF news →
SEC Filings
Silence Therapeutics has filed 10 recent SEC filings, including 2 Form SCHEDULE 13G, 2 Form 8-K, 2 Form SCHEDULE 13G/A, 2 Form 424B5. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SLNCF SEC filings →
Insider Radar
Insider selling at Silence Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Silence Therapeutics generated $559K in revenue in FY2025, retaining a 61.5% gross margin, operating income reached -$91.1M, and net income was -$88.6M. Diluted earnings per share stood at -$0.63. The company generated -$62.3M in operating cash flow. The current ratio was 8.72, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Silence Therapeutics (SLNCF) currently stands at 136 shares, down 94.2% from the previous reporting period, representing 0.0% of the float. Since January 2026, short interest has decreased by 82.0%.
Days to Cover History
Days to cover for Silence Therapeutics (SLNCF) currently stands at 1.0 days, down 99.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since January 2026, the figure has decreased by 41.9%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.
SLNCF Company Profile & Sector Positioning
Silence Therapeutics (SLNCF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing SLNCF often look at related companies in the same sector, including Pharma Mar SA New (PHMMF), Mesoblast Ltd (MEOBF), Pharming Group NV (PHGUF), Oxford Biomedica plc New (OXBDF), and Nxera Pharma Co Ltd (SOLTF). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SLNCF's relative position within its industry.